DOCSLIB.ORG

Anti-Parkinsonian Apis and Impurities Amantadine Hydrochloride

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Parkinsonian Apis and Impurities Amantadine Hydrochloride Anti-Parkinsonian APIs and impurities Code Product CAS No. CS Price Unit Amantadine Hydrochloride NH 2 MM0564.00 Amantadine Hydrochloride 665-66-7 A 500mg HCl Apomorphine Hydrochloride OH H O MM0562.00 Apomorphine Hydrochloride Hemihydrate 41372-20-7 A 250mg HCl H2O 2 N H 2 Imp. B (EP) as Hydrochloride Trihydrate: Morphine N MM0037.00 6055-06-7 CS A 250mg H HCl H2O Hydrochloride Trihydrate 3 H O O O H Benserazide Hydrochloride N H H 2 N OH N HCl H MM1282.00 Benserazide Hydrochloride 14919-77-8 A 250mg O H O OH OH Benztropine Mesilate H O O H S MM1227.00 Benztropine Mesilate 132-17-2 A 250mg N O H O H Bromocriptine Mesilate Br H N O H O H N N N H N MM1159.00 Bromocriptine Mesilate 22260-51-1 A 100mg O O OH O O S OH Caramiphen Hydrochloride O N MM1585.00 Caramiphen Hydrochloride 125-85-9 A 50mg O HCl Carbidopa O OH H2 O MM1501.00 Carbidopa 38821-49-7 A 250mg H N H O N H2 OH Cycrimine Hydrochloride N HCl MM3046.00 Cycrimine Hydrochloride 126-02-3 A 100mg HO Diethazine Hydrochloride N N HCl MM1593.00 Diethazine Hydrochloride 341-70-8 A 50mg S Visit us at www.lgcstandards.com Anti-Parkinsonian APIs and impurities Code Product CAS No. CS Price Unit Entacapone O O N + MM1221.00 Entacapone 130929-57-6 A 250mg O N H O N OH N H O Imp. A (EP): (2Z)-2-Cyano-3-(3,4-dihydroxy- MM1221.02 145195-63-7 A 50mg H O O N 5-nitrophenyl)-N,N-diethylprop-2-enamide + N O O O O N + Imp. B (EP): Ethyl (2E)-2-Cyano-3-(3,4- O O MM1221.04 n/a A 50mg H O dihydroxy-5-nitrophenyl)prop-2-enoate N OH O H O MM1221.01 Imp. C (EP): 3,4-Dihydroxy-5-nitrobenzaldehyde 116313-85-0 A 100mg H O + N O O O O N+ Imp. D (EP): (2E)-2-Cyano-3-(3-ethoxy-4- O N MM1221.05 hydroxy-5-nitrophenyl)-N,N-diethylprop-2- 857629-79-9 A 50mg H O N enamide O O O + + N N MM1221.06 Imp. E (EP): 3,5-Dinitrobenzene-1,2-diol 7659-29-2 A 50mg O O H O OH O O N + Imp. F (EP): (2E)-2-Cyano-3-(3,4-dihydroxy- O OH MM1221.07 160391-70-8 A 50mg 5-nitrophenyl)prop-2-enoic Acid H O N OH O O N + Imp. G (EP): (2E)-2-Cyano-3-(3,4-dihydroxy- O N MM1221.08 n/a A 50mg H 5-nitrophenyl)-N-methylprop-2-enamide H O N OH O O Imp. H (EP): (2E)-3-(3,4-Dihydroxy-5-nitro- + N MM1221.03 phenyl)-2-(piperidin-1-ylcarbonyl)prop-2- 1150310-15-8 A 50mg O N H O N ennitrile OH O O + Imp. I (EP): Propyl (2E)-2-Cyano-3-(3,4- N MM1221.09 n/a A 50mg O O H O dihydroxy-5-nitrophenyl)prop-2-enoate N OH Levodopa O MM0262.00 Levodopa 59-92-7 A 500mg OH N H2 H O OH H O Imp. B (EP): (2S)-2-Amino-3-(4-hydroxyphenyl)propanoic N H2 MM0634.00 60-18-4 A 100mg OH Acid (Tyrosine) O O Imp. C (EP): (2RS)-2-Amino-3-(4-hydroxy-3- OH MM0262.05 methoxyphenyl)propanoic Acid (3-Methoxy- 7636-26-2 A 100mg N H 2 H O DL-tyrosine; (DL)-3-O-Methyldopa) O OH OH MM0262.06 4-Hydroxy-3-methoxymandelic Acid 55-10-7 A 100mg O H O O O MM0262.16 N,N-Dimethyl-L-phenylalanine 17469-89-5 A 100mg OH N Visit us at www.lgcstandards.com Anti-Parkinsonian APIs and impurities Code Product CAS No. CS Price Unit O O MM0262.17 (2S)-2-Amino-3-(3-methoxyphenyl)propanoic Acid 33879-32-2 A 50mg OH N H 2 Memantine Hydrochloride N H 2 MM1045.00 Memantine Hydrochloride 41100-52-1 A 250mg HCl OH MM1045.01 1-Hydroxy-3,5-dimethyladamantane 707-37-9 A 100mg Cl MM1045.04 1-Chloro-3,5-dimethyladamantane 707-36-8 A 100mg Br MM1045.05 1-Bromo-3,5-dimethyladamantane 941-37-7 A 100mg MM1045.06 1,3-Dimethyladamantane 702-79-4 A 100mg O N H MM1045.07 N-Formylmemantine 351329-88-9 A 100mg Metixene Hydrochloride HCl H O MM0125.00 Metixene Hydrochloride Monohydrate 7081-40-5 A 250mg S 2 N MM0125.01 Imp. A (EP): 9H-Thioxanthene 261-31-4 A 100mg S O Imp. B (EP): 9H-Thioxanthen-9-one MM0125.02 492-22-8 B 100mg (Thioxanthone) S Visit us at www.lgcstandards.com Anti-Parkinsonian APIs and impurities Code Product CAS No. CS Price Unit Orphenadrine Citrate O OH O OH MM3601.00 Orphenadrine Citrate 4682-36-4 A 250mg N O OH OH O Orphenadrine Hydrochloride HCl MM0801.00 Orphenadrine Hydrochloride 341-69-5 A 500mg N O Imp. A (EP): (RS)-(2-Methylphenyl)phenylmethanol MM0801.01 5472-13-9 A 100mg (2-Methylbenzhydrol) OH Imp. B (EP): (2-Methylphenyl)phenylmethanone MM0801.02 131-58-8 A 100mg (2-Methylbenzophenone) O Imp. C (EP) as Hydrochloride: (RS)-2-[(2-Methyl- MM0801.03 17752-32-8 A 50mg HCl N H 2 phenyl)phenylmethoxy]ethanamine Hydrochloride O Imp. D (EP) as Hydrochloride: Diphenhydramine HCl MM0490.00 147-24-0 A 500mg N Hydrochloride O Imp. E (EP) as Hydrochloride: (RS)-N,N-Dimethyl- 2-[(3-methylphenyl)phenylmethoxy]ethanamine MM0801.05 17630-53-4 A 100mg N HCl Hydrochloride (meta-Methylbenzyl Isomer O Hydrochloride) Imp. F (EP) as Hydrochloride: (RS)-N,N-Dimethyl- 2-[(4-methylphenyl)phenylmethoxy]ethanamine HCl MM0490.04 Hydrochloride (para-Methylbenzyl Isomer Hydro- 4024-34-4 A 100mg N chloride; 4-Methyldiphenhydramine Hydrochloride) O H HCl MM0801.07 N-Desmethylorphenadrine Hydrochloride 10488-36-5 A 100mg N O N-Ethyl-N,N-dimethyl-[2-(2-methylbenzhydryloxy)ethyl] + Cl MM0801.08 93940-17-1 A 100mg N ammonium Chloride O Phenglutarimide Hydrochloride H O N O N MM3210.00 Phenglutarimide Hydrochloride 1674-96-0 A 50mg HCl Pimavanserin Hemitartrat O N N H MM3578.01 Pimavanserin 706779-91-1 A 100mg F O N Visit us at www.lgcstandards.com Anti-Parkinsonian APIs and impurities Code Product CAS No. CS Price Unit Pramipexole Dihydrochloride Monohydrate H N S MM0332.01 Pramipexole Dihydrochloride Monohydrate 191217-81-9 A 250mg N H 2 HCl H2O N 2 Imp. A (EP): (6S)-4,5,6,7-Tetrahydro-1,3- H2 N S MM0332.02 106092-09-5 A 100mg N H 2 benzothiazole-2,6-diamine N Imp. A (EP) as Racemate: (6RS)-4,5,6,7-Tetrahydro-1,3- H2 N S MM0332.09 104617-49-4 A 100mg N H 2 benzothiazole-2,6-diamine N H Imp. D (EP): (6R)-6-N-Propyl-4,5,6,7-tetrahydro-1,3- N MM0332.07 104632-28-2 A 100mg S N H 2 benzothiazole-2,6-diamine N H2 N S MM0332.08 (6R)-4,5,6,7-Tetrahydro-1,3-benzothiazole-2,6-diamine 106092-11-9 A 100mg N H 2 N Pridinol Hydrochloride N HCl MM1177.00 Pridinol Hydrochloride 968-58-1 A 100mg OH N MM3493.01 1,1-Diphenyl-3-(N-piperidino)prop-1-ene Hydrochloride 30778-27-9 A 100mg HCl Procyclidine Hydrochloride H O MM1573.00 Procyclidine Hydrochloride 1508-76-5 A 100mg HCl N Ropinirole Hydrochloride H N Ropinirole Hydrochloride O MM0331.00 91374-20-8 A 250mg HCl available as Quantitative Standard LGCQUANT0331.00 N H N O MM0331.02 4-[2-(Dipropylamino)ethyl]indoline-2,3-dione Hydrochloride 221264-21-7 A 50mg HCl N O H N MM0331.08 4-(2-Hydroxyethyl)indolin-2-one 139122-19-3 A 100mg O H O Rotigotine Hydrochloride OH MM1403.00 Rotigotine 99755-59-6 A 100mg N S OH Despropylrotigotine ((6S)-5,6,7,8-Tetrahydro-6-[[2-(2- MM1403.02 153409-14-4 A 50mg thienyl)ethyl]amino]-1-naphthalenol) N S H O OH MM1403.03 (S)-2-Amino-5-methoxytetralin (S)-Mandelate 439133-67-2 A 100mg OH O N H 2 O MM1403.04 Despropylrotigotine Methyl Ether Hydrochloride 1232344-35-2 A 100mg HCl N S H Visit us at www.lgcstandards.com Anti-Parkinsonian APIs and impurities Code Product CAS No. CS Price Unit OH HCl MM1403.10 Rotigotine N-Oxide Hydrochloride n/a A 50mg + N S O Selegiline Hydrochloride MM0216.00 Selegiline Hydrochloride 14611-52-0 A 100mg N HCl Imp. A (EP) as Hydrochloride: (2RS)-N-Methyl-1- H phenylpropan-2-amine Hydrochloride ((RS)- N MM0964.03 300-42-5 CS A 100mg Metamfetamine Hydrochloride; rac-Methamphetamine HCl Hydrochloride) Imp. B (EP) as Racemate Sulfate:(2RS)-1-Phenylpropan- N H 2 O O MM0741.00 60-13-9 A 100mg S 2-amine Sulfate (rac-Amfetamine Sulfate; Amfetamine CS H O OH Sulfate) 2 Imp. C (EP) as Hydrochloride: (1RS, 2SR)-2- AND Enantiomer OH N H HCl MM0656.00 Amino-1-phenylpropan-1-ol Hydrochloride 154-41-6 A 500mg 2 (Phenylpropanolamine Hydrochloride) Imp. D (EP) as Racemate Hydrochloride: H N-[(1RS)-1-Methyl-2-phenylethyl]prop-2-yn-1- N MM0216.09 2588-96-7 A 100mg amine Hydrochloride (rac-Demethylselegiline HCl Hydrochloride) Tolcapone O MM3329.02 4'-Methyl-3,4-dihydroxybenzophenone 1391053-03-4 A 100mg H O H O O O MM3329.01 4-Hydroxy-3-methoxy-4'-methyl-5-nitrobenzophenone 134612-80-9 A 100mg H O + N O O Trihexyphenidyl Hydrochloride OH MM0237.00 Trihexyphenidyl Hydrochloride 52-49-3 A 500mg HCl N Imp.
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep
    United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep. 10, 1985 54 BRAIN-SPECIFICDRUG DELIVERY 57 ABSTRACT 75 Inventor: Nicholas S. Bodor, Gainesville, Fla. The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug 73) Assignee: University of Florida, Gainesville, species to the brain, are: Fla. (a) compounds of the formula 21 Appl. No.: 516,382 22 Filed: Jul. 22, 1983 D-DHC) (I) Related U.S. Application Data wherein D is a centrally acting drug species, and 63 Continuation-in-part of Ser. No. 379,316, May 18, DHC is the reduced, biooxidizable, blood-brain 1982, Pat. No. 4,479,932, Ser. No. 461,543, Jan. 27, barrier penetrating lipoidal form of a dihydropyri 1983, , and Ser. No. 475,493, Mar. 15, 1983, , said Ser. dine - pyridinium salt redox carrier, with the No. 46,543, and Ser. No. 475,493, each is a continua proviso that when DHC) is tion-in-part of Ser. No. 379,316. 30 Foreign Application Priority Data O May 12, 1983 WO, PCT Int'l Appl. ......... WO83/00725 May 16, 1983 ICA) Canada ................................... 42892 51) Int. Cl...................... A61K 49/00; A61K 31/58; r’sN CO7J 17/00 52 U.S. Cl. ..................................... 424/9; 260/239.5; R 514/176 58 Field of Search .................. 424/9, 241; 260/239.5 wherein R is lower alkyl or benzyl and D is a drug species containing a single NH2 or OH func 56 References Cited tional group, the single OH group when present U.S.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Recent Advances in the Treatment of Parkinson's Disease
    Recent advances in the treatment of Parkinsonism Parkinsons disease RICHARD J. MARTOCCI, D.O. Highland Park, Michigan ticholinergic drugs conventionally used to treat par- kinsonism, levodopa was three-and-a-half times as Although there are both medical and effective in relieving symptoms. However, the surgical methods of treating treatment of paralysis agitans, whether medical or parkinsonism, medical therapy should surgical, remains purely palliative and never is cura- be tried first and surgical measures tive. reserved for patients who do not respond. Anticholinergic drugs may be Pathophysiologic and biochemical aspects combined with an antihistamine when The pathologic alterations in parkinsonism the symptoms are mild, and levodopa (paralysis agitans) most consistently affect the zona used alone or with another drug when compacta2 of the substantia nigra with formation of the disease is moderate to severe. The Lewy bodies, or inclusion bodies, and neurofibril- side effects of levodopa are lary tangles3 such as those in Alzheimers disease and troublesome, and the clinical program other forms of senile atrophy. Histochemical studies must be adjusted constantly to achieve using fluorescent techniques have shown that maximum benefits and minimum side dopamine is almost nonexistent in the neostriatum effects. Pyridoxine reverses side effects and substantia nigra. Dopamine, a catecholamine, but also the benefits of levodopa. Use of has proved to be a neurohumeral transmitter. This a peripheral decarboxylase inhibitor suggests that in parkinsonism there is a decrease in may permit reduction in the dose of ability of affected brain tissue to form dopamine, levodopa to a point that side effects can and from 80 to 90 percent of dopamine in the brain be minimal.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]